PALENA THERAPEUTICS, INC.

Biotech · Private

Novel peptide compounds that bind MHC class II molecules to reprogram immune responses from pro- to anti-inflammatory

Grants
$305K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
1
0 granted · 1 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantNational Science Foundation · Phase I · SBIR Phase I: Novel Peptide Immunomodulators for Treatment of Autoimmune and Inflammatory Disorders$305,000
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1154LOHOCLA RESEARCH CORPORATION——
1155ENSIGN PHARMACEUTICAL, INC.——
1156ALLIANCE DISCOVERY, INC.——
1157PALENA THERAPEUTICS, INC.——
1158ASTRAEA THERAPEUTICS, LLC——
1159NEUTHERAPEUTICS, LLC——
1160IMAGO PHARMACEUTICALS, INC.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 1
  • Compositions Of Embedded Epitope Random Peptides (eerp) For Treatment Of Immune-mediated Conditions, And Methods Of Useapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.